면역조절제 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of immunomodulators Market

The global immunomodulators market size was valued at USD 250.69 billion in 2025 and is projected to grow from USD 269.15 billion in 2026 to USD 475.04 billion by 2034, registering a CAGR of 7.36% during 2026-2034. North America dominated the global market with a 38.32% share in 2025, supported by the high prevalence of autoimmune and chronic diseases, strong pharmaceutical research, clinical development, and product launches.

Immunomodulators are medicines that regulate immune-system activity by either suppressing or stimulating immune responses. Immunosuppressants are widely used for autoimmune disorders and to prevent organ rejection following transplantation, while immunostimulants include vaccines, antibodies, and other therapies that enhance immune responses. Increasing research into multiple sclerosis, rheumatoid arthritis, Crohn's disease, cancer, respiratory disorders, and other conditions is supporting demand for advanced immunomodulatory therapies.

Market Definition and Scope

The immunomodulators market covers pharmaceutical products that modify immune-system activity. The market is broadly classified into immunosuppressants and immunostimulants, with applications across oncology, respiratory diseases, HIV, autoimmune disorders, transplantation, and other medical conditions. The market also includes products developed and supplied through pharmaceutical and biotechnology companies, healthcare facilities, and related healthcare channels.

Market Dynamics

Drivers

The increasing prevalence of autoimmune diseases is a major factor driving market growth. Conditions such as multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease create significant demand for therapies that can regulate abnormal immune responses. Expanding clinical trials and the development of new immunotherapeutic agents are also contributing to the growing product pipeline.

The strong drug pipeline provides additional growth opportunities. Pharmaceutical and biotechnology companies are investing in combination therapies, biologics, targeted treatments, and novel immunomodulators to address unmet medical needs. Increasing research into cancer immunotherapy is also broadening the potential applications of immune-modulating medicines.

Trends

Robust research and development is a major trend in the market. Companies are increasingly focusing on immunotherapy, targeted drug therapy, monoclonal antibodies, and advanced treatments for cancer and autoimmune disorders. Strategic collaborations and partnerships are helping companies accelerate clinical development and commercialization.

Restraints

Adverse effects associated with immunomodulatory drugs can restrict market expansion. Immunosuppressive therapies may increase the risk of infections and other complications, while some treatments can cause fatigue, gastrointestinal problems, skin disorders, and other side effects. In addition, stringent regulatory requirements for clinical studies and product approvals can increase development timelines and costs.

Impact of COVID-19

The COVID-19 pandemic had a positive impact on the immunomodulators market in several areas because of increased demand for medicines and greater attention toward immune-related treatments. Pharmaceutical companies strengthened supply-chain management, manufacturing capabilities, quality control, and research activities to maintain product availability. The pandemic also encouraged research into immune-modulating approaches and potential supportive therapies.

Segmentation Analysis

By Product Type

The market is segmented into immunosuppressants and immunostimulants. Immunosuppressants held the largest market share, supported by their broad use in autoimmune diseases and transplantation. The immunostimulants segment is expected to witness strong growth as demand increases for vaccines, antibodies, and therapies designed to enhance immune responses.

By Application

Applications include oncology, respiratory, HIV, and others, with the other category covering conditions such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease. The respiratory segment is expected to account for a 37.9% share in 2025, while increasing cancer prevalence and growing adoption of immunotherapy are supporting the oncology segment.

Regional Insights

North America

North America generated USD 61.91 billion in 2025 and accounted for a 38.32% market share. High disease prevalence, strong pharmaceutical infrastructure, clinical research, and the presence of major market players support the region's leading position. The U.S. represents the largest contributor within the region.

Europe

Europe is an important market supported by pharmaceutical R&D investments and increasing sales of immunosuppressant drugs. The region is projected to grow at a CAGR of 6.2% during the forecast period.

Asia Pacific

Asia Pacific is projected to record strong growth, supported by increasing clinical studies, expanding healthcare infrastructure, and a growing geriatric population. China is projected to register a CAGR of 7.00%, while the immunomodulators market in Japan is expected to reach USD 7.70 billion in 2025.

Middle East & Africa and Latin America

These regions are expected to experience comparatively slower growth due to lower adoption of expensive therapies, limited healthcare infrastructure, and fewer product approvals in some developing countries.

Competitive Landscape

Major companies operating in the immunomodulators market include F. Hoffmann-La Roche Ltd., Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., and Eli Lilly and Company. Companies are focusing on R&D, strategic acquisitions, product launches, clinical development, and regulatory approvals to expand their portfolios.

Report Coverage

The immunomodulators market report covers market size and forecast, product types, applications, regional markets, leading companies, market trends, growth drivers, restraints, competitive developments, and industry opportunities. It also evaluates the impact of clinical research, drug pipelines, regulatory factors, and increasing demand for advanced immune-modulating therapies.

Conclusion

The global immunomodulators market is expected to expand from USD 250.69 billion in 2025 to USD 269.15 billion in 2026 and reach USD 475.04 billion by 2034, at a CAGR of 7.36%. Rising autoimmune and chronic disease prevalence, expanding clinical research, strong drug pipelines, and increasing applications in oncology and respiratory diseases are supporting market development. North America remains the leading regional market, while Asia Pacific is expected to experience strong growth during the forecast period.

Unit Value (USD Billion)

Segmentation Product Type; Application; and Region

By Product Type

• Immunosuppressants
• Immunostimulants

By Application

• Respiratory
• Oncology Multiple Sclerosis
• Others

By Geography

• North America
  • By Product Type
  • By Application
  • By Country
• USA (By Product Type)
• Canada (By Product Type)
• Europe
  • By Product Type
  • By Application
  • By Country
• UK (By Product Type)
• Germany (By Product Type)
• France (By Product Type)
• Italy (By Product Type)
• Spain (By Product Type)
• Scandinavia (By Product Type)
• Rest of Europe (By Product Type)
• Asia Pacific
  • By Product Type
  • By Application
  • By Country
• Japan (By Product Type)
• China (By Product Type)
• Australia (By Product Type)
• India (By Product Type)
• Southeast Asia (By Product Type)
• Rest of Asia Pacific (By Product Type)
• Latin America
  • By Product Type
  • By Application
  • By Country
• Brazil (By Product Type)
• Mexico (By Product Type)
• Rest of Latin America (By Product Type)
• The Middle East & Africa
  • By Product Type
  • By Application
  • By Country
• GCC (By Product Type)
• South Africa (By Product Type)
• Rest of Middle East & Africa (By Product Type)

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Key Disease Conditions -Key Regions/Country
• 4.2. New Product Launch
• 4.3. Pipeline Analysis
• 4.4. Impact of COVID-19 on the Immunomodulators Market
• 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships

5. Global Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Product Type
  • 5.2.1. Immunosuppressants
  • 5.2.2. Immunostimulants
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Respiratory
  • 5.3.2. Oncology
  • 5.3.3. Multiple Sclerosis
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Geography
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Product Type
  • 6.2.1. Immunosuppressants
  • 6.2.2. Immunostimulants
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Respiratory
  • 6.3.2. Oncology
  • 6.3.3. Multiple Sclerosis
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Product Type
      • 6.4.1.1.1. Immunosuppressants
      • 6.4.1.1.2. Immunostimulants
  • 6.4.2. Canada
    • 6.4.2.1. By Product Type
      • 6.4.2.1.1. Immunosuppressants
      • 6.4.2.1.2. Immunostimulants

7. Europe Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Product Type
  • 7.2.1. Immunosuppressants
  • 7.2.2. Immunostimulants
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Respiratory
  • 7.3.2. Oncology
  • 7.3.3. Multiple Sclerosis
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
    • 7.4.1.1. By Product Type
      • 7.4.1.1.1. Immunosuppressants
      • 7.4.1.1.2. Immunostimulants
  • 7.4.2. Germany
    • 7.4.2.1. By Product Type
      • 7.4.2.1.1. Immunosuppressants
      • 7.4.2.1.2. Immunostimulants
  • 7.4.3. France
    • 7.4.3.1. By Product Type
      • 7.4.3.1.1. Immunosuppressants
      • 7.4.3.1.2. Immunostimulants
  • 7.4.4. Spain
    • 7.4.4.1. By Product Type
      • 7.4.4.1.1. Immunosuppressants
      • 7.4.4.1.2. Immunostimulants
  • 7.4.5. Italy
    • 7.4.5.1. By Product Type
      • 7.4.5.1.1. Immunosuppressants
      • 7.4.5.1.2. Immunostimulants
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Product Type
      • 7.4.6.1.1. Immunosuppressants
      • 7.4.6.1.2. Immunostimulants
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Product Type
      • 7.4.7.1.1. Immunosuppressants
      • 7.4.7.1.2. Immunostimulants

8. Asia Pacific Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Product Type
  • 8.2.1. Immunosuppressants
  • 8.2.2. Immunostimulants
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Respiratory
  • 8.3.2. Oncology
  • 8.3.3. Multiple Sclerosis
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
    • 8.4.1.1. By Product Type
      • 8.4.1.1.1. Immunosuppressants
      • 8.4.1.1.2. Immunostimulants
  • 8.4.2. China
    • 8.4.2.1. By Product Type
      • 8.4.2.1.1. Immunosuppressants
      • 8.4.2.1.2. Immunostimulants
  • 8.4.3. India
    • 8.4.3.1. By Product Type
      • 8.4.3.1.1. Immunosuppressants
      • 8.4.3.1.2. Immunostimulants
  • 8.4.4. Australia
    • 8.4.4.1. By Product Type
      • 8.4.4.1.1. Immunosuppressants
      • 8.4.4.1.2. Immunostimulants
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Product Type
      • 8.4.5.1.1. Immunosuppressants
      • 8.4.5.1.2. Immunostimulants
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Product Type
      • 8.4.6.1.1. Immunosuppressants
      • 8.4.6.1.2. Immunostimulants

9. Latin America Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Product Type
  • 9.2.1. Immunosuppressants
  • 9.2.2. Immunostimulants
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Respiratory
  • 9.3.2. Oncology
  • 9.3.3. Multiple Sclerosis
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Product Type
      • 9.4.1.1.1. Immunosuppressants
      • 9.4.1.1.2. Immunostimulants
  • 9.4.2. Mexico
    • 9.4.2.1. By Product Type
      • 9.4.2.1.1. Immunosuppressants
      • 9.4.2.1.2. Immunostimulants
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Product Type
      • 9.4.3.1.1. Immunosuppressants
      • 9.4.3.1.2. Immunostimulants

10. Middle East & Africa Immunomodulators Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Product Type
  • 10.2.1. Immunosuppressants
  • 10.2.2. Immunostimulants
• 10.3. Market Analysis, Insights and Forecast - By Application
  • 10.3.1. Respiratory
  • 10.3.2. Oncology
  • 10.3.3. Multiple Sclerosis
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
    • 10.4.1.1. By Product Type
      • 10.4.1.1.1. Immunosuppressants
      • 10.4.1.1.2. Immunostimulants
  • 10.4.2. South Africa
    • 10.4.2.1. By Product Type
      • 10.4.2.1.1. Immunosuppressants
      • 10.4.2.1.2. Immunostimulants
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Product Type
      • 10.4.3.1.1. Immunosuppressants
      • 10.4.3.1.2. Immunostimulants

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Company Profiles
  • 11.3.1. F. Hoffmann-La Roche Ltd
    • 11.3.1.1. Overview,
    • 11.3.1.2. Product Types & Services,
    • 11.3.1.3. SWOT Analysis,
    • 11.3.1.4. Recent Developments,
    • 11.3.1.5. Strategies,
    • 11.3.1.6. Financials (Based on Availability)
  • 11.3.2. Novartis AG
    • 11.3.2.1. Overview,
    • 11.3.2.2. Product Types & Services,
    • 11.3.2.3. SWOT Analysis,
    • 11.3.2.4. Recent Developments,
    • 11.3.2.5. Strategies,
    • 11.3.2.6. Financials (Based on Availability)
  • 11.3.3. Biogen
    • 11.3.3.1. Overview,
    • 11.3.3.2. Product Types & Services,
    • 11.3.3.3. SWOT Analysis,
    • 11.3.3.4. Recent Developments,
    • 11.3.3.5. Strategies,
    • 11.3.3.6. Financials (Based on Availability)
  • 11.3.4. Teva Pharmaceutical Industries Ltd.
    • 11.3.4.1. Overview,
    • 11.3.4.2. Product Types & Services,
    • 11.3.4.3. SWOT Analysis,
    • 11.3.4.4. Recent Developments,
    • 11.3.4.5. Strategies,
    • 11.3.4.6. Financials (Based on Availability)
  • 11.3.5. Amgen, Inc
    • 11.3.5.1. Overview,
    • 11.3.5.2. Product Types & Services,
    • 11.3.5.3. SWOT Analysis,
    • 11.3.5.4. Recent Developments,
    • 11.3.5.5. Strategies,
    • 11.3.5.6. Financials (Based on Availability)
  • 11.3.6. Bristol-Myers & Squibb Company
    • 11.3.6.1. Overview,
    • 11.3.6.2. Product Types & Services,
    • 11.3.6.3. SWOT Analysis,
    • 11.3.6.4. Recent Developments,
    • 11.3.6.5. Strategies,
    • 11.3.6.6. Financials (Based on Availability)
  • 11.3.7. Merck Sharp & Dohme Corp.
    • 11.3.7.1. Overview,
    • 11.3.7.2. Product Types & Services,
    • 11.3.7.3. SWOT Analysis,
    • 11.3.7.4. Recent Developments,
    • 11.3.7.5. Strategies,
    • 11.3.7.6. Financials (Based on Availability)
  • 11.3.8. Eli Lilly and Company
    • 11.3.8.1. Overview,
    • 11.3.8.2. Product Types & Services,
    • 11.3.8.3. SWOT Analysis,
    • 11.3.8.4. Recent Developments,
    • 11.3.8.5. Strategies,
    • 11.3.8.6. Financials (Based on Availability)
  • 11.3.9. Other Prominent Players
    • 11.3.9.1. Overview,
    • 11.3.9.2. Product Types & Services,
    • 11.3.9.3. SWOT Analysis,
    • 11.3.9.4. Recent Developments,
    • 11.3.9.5. Strategies,
    • 11.3.9.6. Financials (Based on Availability)

12. Strategic Recommendations